X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $243M; returns 1 day +1.3%, 1 week +25.1%, 1 year +4.9%.

X4 Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases of the immune system. Their primary focus is on conditions with significant unmet medical needs. X4's lead product is mavorixafor, an oral, once-daily CXCR4 antagonist. Mavorixafor is marketed in the U.S.

Groups XFOR belongs to

• Biotechnology
• Biopharmaceutical
• Rare Diseases
• Commercial Stage Biotech
• Healthcare
• Life Sciences
• Unmet Medical Needs
• Pharmaceuticals
• Hematology

XFOR financial model: income statement, cash flow and balance sheet